Grifols/$GRFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Ticker
$GRFS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
23,800
ISIN
US3984384087
Website
Grifols Metrics
BasicAdvanced
$8.2B
29.18
$0.33
1.01
-
Price and volume
Market cap
$8.2B
Beta
1.01
52-week high
$9.85
52-week low
$6.19
Average daily volume
760K
Financial strength
Current ratio
2.599
Quick ratio
0.942
Long term debt to equity
113.214
Total debt to equity
121.139
Dividend payout ratio (TTM)
0.49%
Interest coverage (TTM)
2.29%
Profitability
EBITDA (TTM)
1,945.026
Gross margin (TTM)
39.39%
Net profit margin (TTM)
2.65%
Operating margin (TTM)
18.59%
Effective tax rate (TTM)
44.76%
Revenue per employee (TTM)
$361,980
Management effectiveness
Return on assets (TTM)
3.99%
Return on equity (TTM)
3.45%
Valuation
Price to earnings (TTM)
29.182
Price to revenue (TTM)
0.771
Price to book
1.25
Price to tangible book (TTM)
-1.26
Price to free cash flow (TTM)
7.07
Free cash flow yield (TTM)
14.14%
Free cash flow per share (TTM)
137.91%
Growth
Revenue change (TTM)
10.76%
3-year revenue growth (CAGR)
13.70%
10-year revenue growth (CAGR)
7.84%
10-year earnings per share growth (CAGR)
-8.57%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Bulls say / Bears say
Grifols reported a 10.2% increase in revenues for 2024, reaching €7.21 billion, surpassing its 7% growth target. (reuters.com)
The company successfully completed the delisting of its German subsidiary, Biotest, enhancing operational efficiency and consolidating its market position. (cincodias.elpais.com)
Moody's upgraded Grifols' corporate family debt rating to B2 with a positive outlook, reflecting improved financial health. (grifols.com)
The hedge fund Rokos Global Macro Master Fund reduced its stake in Grifols to below 1%, indicating potential concerns about the company's future performance. (cincodias.elpais.com)
Grifols faced significant deficiencies in its financial reports as identified by Spain's National Securities Market Commission, which could undermine investor confidence. (catalannews.com)
Brookfield Asset Management withdrew its $6 billion takeover offer for Grifols, suggesting potential disagreements over the company's valuation and future prospects. (biospace.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Grifols News
AllArticlesVideos
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
GlobeNewsWire·1 month ago
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
Business Wire·1 month ago
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $8.2B as of July 11, 2025.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 29.18 as of July 11, 2025.
Does Grifols stock pay dividends?
No, Grifols (GRFS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Grifols dividend payment date?
Grifols (GRFS) stock does not pay dividends to its shareholders.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.